Find the right fit for you - faster

Get tailored insights about working at FibroGen in one quick step.

FibroGen Snapshot

3.9
based on 132 ratings

75% would recommend to a friend

avatar

Thane Wettig

100% approve of CEO

Description FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and metastatic pancreatic cancer. For more information, please visit www.fibrogen.com.

Life at FibroGen

Glassdoor gives you an inside look at what it's like to work at FibroGen, including salaries, reviews, office photos, and more. This is the FibroGen company profile. All content is posted anonymously by employees working at FibroGen.